Blueprint Medicines Corporation (BPMC): Price and Financial Metrics

Blueprint Medicines Corporation (BPMC): $106.61

-2.86 (-2.61%)

POWR Rating

Component Grades













Add BPMC to Watchlist
Sign Up

Industry: Biotech


of 505

in industry


  • Value is the dimension where BPMC ranks best; there it ranks ahead of 92.82% of US stocks.
  • The strongest trend for BPMC is in Momentum, which has been heading down over the past 48 weeks.
  • BPMC's current lowest rank is in the Growth metric (where it is better than 5.36% of US stocks).

BPMC Stock Summary

  • Equity multiplier, or assets relative to shareholders' equity, comes in at 1.17 for Blueprint Medicines Corp; that's greater than it is for just 11.15% of US stocks.
  • Over the past twelve months, BPMC has reported earnings growth of -181.77%, putting it ahead of merely 11.43% of US stocks in our set.
  • As for revenue growth, note that BPMC's revenue has grown 1,001.45% over the past 12 months; that beats the revenue growth of 98.89% of US companies in our set.
  • Stocks with similar financial metrics, market capitalization, and price volatility to Blueprint Medicines Corp are DCPH, RYTM, DNLI, FIXX, and ZGNX.
  • Visit BPMC's SEC page to see the company's official filings. To visit the company's web site, go to

BPMC Valuation Summary

  • In comparison to the median Healthcare stock, BPMC's price/earnings ratio is 55.89% lower, now standing at 16.1.
  • Over the past 77 months, BPMC's price/earnings ratio has gone up 26.3.
  • BPMC's EV/EBIT ratio has moved up 25.6 over the prior 77 months.

Below are key valuation metrics over time for BPMC.

Stock Date P/S P/B P/E EV/EBIT
BPMC 2021-08-31 6.6 4.1 16.1 14.8
BPMC 2021-08-30 6.7 4.1 16.2 15.0
BPMC 2021-08-27 6.6 4.1 16.1 14.9
BPMC 2021-08-26 6.6 4.1 16.0 14.7
BPMC 2021-08-25 6.6 4.1 16.2 14.9
BPMC 2021-08-24 6.7 4.2 16.3 15.1

BPMC's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • BPMC has a Quality Grade of B, ranking ahead of 83.77% of graded US stocks.
  • BPMC's asset turnover comes in at 0.512 -- ranking 82nd of 677 Pharmaceutical Products stocks.
  • VTGN, SVRA, and SGEN are the stocks whose asset turnover ratios are most correlated with BPMC.

The table below shows BPMC's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.512 0.992 0.352
2021-03-31 0.566 0.999 0.382
2020-12-31 0.634 0.999 0.411
2020-09-30 0.812 1.000 0.485
2020-06-30 0.095 0.998 -0.729
2020-03-31 0.091 1.000 -0.623

BPMC Price Target

For more insight on analysts targets of BPMC, see our BPMC price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $119.69 Average Broker Recommendation 1.43 (Moderate Buy)

BPMC Stock Price Chart Interactive Chart >

Price chart for BPMC

BPMC Price/Volume Stats

Current price $106.61 52-week high $125.61
Prev. close $109.47 52-week low $79.07
Day low $106.45 Volume 189,100
Day high $109.05 Avg. volume 462,330
50-day MA $93.97 Dividend yield N/A
200-day MA $96.48 Market Cap 6.24B

Blueprint Medicines Corporation (BPMC) Company Bio

Blueprint Medicines Corporation makes kinase drugs to treat patients with genomically defined diseases. The company was founded in 2008 and is based in Cambridge, Massachusetts.

BPMC Latest News Stream

Event/Time News Detail
Loading, please wait...

BPMC Latest Social Stream

Loading social stream, please wait...

View Full BPMC Social Stream

Latest BPMC News From Around the Web

Below are the latest news stories about Blueprint Medicines Corp that investors may wish to consider to help them evaluate BPMC as an investment opportunity.

Blueprint Medicines Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Blueprint Medicines Corporation (NASDAQ: BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunotherapy, today announced that, effective on September 1, 2021, the Compensation Committee of Blueprint Medicines' Board of Directors granted non-qualified stock options to purchase an aggregate of 23,720 shares of its common stock and an aggregate of 11,858 restricted stock units (RSUs) to 12 new employees under Blueprint Medicines' 2020 Inducement Pl

Yahoo | September 3, 2021

Blueprint Medicines to Present at Morgan Stanley 19th Annual Global Healthcare Conference

Blueprint Medicines Corporation (NASDAQ: BPMC) today announced that Kate Haviland, Blueprint Medicines' Chief Operating Officer, and Fouad Namouni, M.D., Blueprint Medicines' President, Research & Development, will participate virtually in a fireside chat at the Morgan Stanley 19th Annual Global Healthcare Conference on Thursday, September 9, 2021 at 12:30 p.m. ET.

Yahoo | September 2, 2021

Is Blueprint Medicines Corporation's (NASDAQ:BPMC) Latest Stock Performance A Reflection Of Its Financial Health?

Blueprint Medicines (NASDAQ:BPMC) has had a great run on the share market with its stock up by a significant 12% over...

Yahoo | August 25, 2021

Ex-Peloton Therapeutics CEO launches biotech startup with $60M

Two years after Peloton Therapeutics was acquired by Merck & Co. Inc. (NYSE: MRK), Peloton CEO John A. Josey is leading a new startup based on technology out of the Howard Hughes Medical Institute and the University of Texas Southwestern Medical Center.

Yahoo | August 24, 2021

STAT+: STAT+ Conversation: Blueprint for cancer drugs

STAT''s Nicholas St. Fleur sits down with Fouad Namouni of Blueprint Medicines to discuss the future of oncology.

STAT News | August 10, 2021

Read More 'BPMC' Stories Here

BPMC Price Returns

1-mo 13.69%
3-mo 21.73%
6-mo 9.65%
1-year 21.15%
3-year 36.57%
5-year 273.94%
YTD -4.94%
2020 40.00%
2019 48.60%
2018 -28.51%
2017 168.84%
2016 6.49%

Continue Researching BPMC

Want to see what other sources are saying about Blueprint Medicines Corp's financials and stock price? Try the links below:

Blueprint Medicines Corp (BPMC) Stock Price | Nasdaq
Blueprint Medicines Corp (BPMC) Stock Quote, History and News - Yahoo Finance
Blueprint Medicines Corp (BPMC) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.9368 seconds.